Abimbola Olubukunola Opadeyi

Abimbola Olubukunola Opadeyi

Auto-generated profile, based on publicly available information

Abimbola Olubukunola Opadeyi

Department of Clinical Pharmacology and Therapeutics University of Benin Benin City Nigeria

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Annals of African Medicine
Verified
Journal Article
Open access
PDF file
AOAbimbolaO Olowofela
AbimbolaO Olowofela
AIAmbroseO Isah
AmbroseO Isah
Background: There has been a dearth of comprehensive data on the profile of adverse reactions to antihypertensive medicines in the Nigerian setting despite increased use. Objective: This study was aimed to characterize the adverse reactions experienced in the homogenously black African population. Methods: The study was carried out at the University of Benin Teaching Hospital, Benin City, Nigeria, in consenting eligible hypertensive patients ≥18 years. Adverse reactions were sought using patient's self-report and a medicine-induced symptom checklist. Results: A total of 514 patients (340 females) aged 22–97 years were studied. Thirteen percent, 27.6%, 26.7%, 22.0%, and 10.7% were on 1, 2, 3, 4, and ≥5 medicines, respectively, for control of their blood pressure with the frequency of adverse effects increasing proportionately up to four medicines. Adverse reactions to antihypertensive medicines were reported by a total of 93 (18.1%) patients. Diuretics – 27.9%, calcium channel blockers (CCBs) – 26.8%, and angiotensin-converting enzyme inhibitors (ACEIs) – 26.8% accounted for most of the adverse reactions seen, notably frequent micturition and headaches (CCB); excessive micturition and dizziness (diuretics); dry irritating cough (ACEI). Notable complaints for all patients using the checklist were increased frequency of micturition, reduction in libido, and headaches. The reactions resulted in the discontinuation and substitution of therapy in 49.5% of the patients. Conclusions: The characterization of these reactions in Nigerians requires further studies as frequent micturition reported is still a neglected complaint in antihypertensive therapy. Résumé Contexte: Il y a eu une pénurie de données complètes sur le profil des réactions indésirables aux médicaments antihypertenseurs dans le cadre nigérian malgré une utilisation accrue. Objectif: Cette étude visait à caractériser les effets indésirables de la population africaine homogène noir. Méthodes: L'étude a été réalisée à l'hôpital universitaire de l'Université du Bénin, dans la ville de Benin, au Nigeria, dans des patients hypertendus admissibles ≥18 ans qui ont consenti à l'étude. Des réactions indésirables ont été recherchées en utilisant l'auto-évaluation du patient et une liste de contrôle des symptômes induite par un médicament. Résultats: Un total de 514 patients (340 femmes) âgés de 22 à 97 ans ont été étudiés. Treize pour cent, 27,6%, 26,7%, 22,0% et 10,7% étaient en 1, 2, 3, 4 et ≥5 médicaments, respectivement, pour le contrôle de leur pression artérielle avec la fréquence des effets indésirables augmentant proportionnellement jusqu'à quatre médicaments. Les réactions indésirables aux antihypertenseurs ont été rapportées par un total de 93 patients (18,1%). Les diurétiques - 27,9%, les inhibiteurs des canaux calciques (CCB) - 26,8% et les inhibiteurs de l'enzyme de conversion de l'angiotensine (ACEI) - 26,8% ont représenté la plupart des effets indésirables observés, notamment la miction et les maux de tête fréquents (CCB); Miction excessive et vertiges (diurétiques); Toux irritante sèche (ACEI). Des plaintes notables pour tous les patients utilisant la liste de contrôle étaient une fréquence accrue de miction, une réduction de la libido et des maux de tête. Les réactions ont entraîné l'arrêt et la substitution du traitement chez 49,5% des patients. Conclusions: La caractérisation de ces réactions chez les Nigérians nécessite d'autres études car les miction fréquentes rapportées sont encore une plainte négligée dans le traitement antihypertenseur. Mots-clés: Effets indésirables des médicaments, agents antihypertenseurs, Nigéria

12 January 2022 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
OOOgochukwu Okoye
Ogochukwu Okoye
OAOluseyi Ademola Adejumo
Oluseyi Ademola Adejumo
AOAbimbola Olubukunola Opadeyi
Abimbola Olubukunola Opadeyi
CMCynthia Roli Madubuko
Cynthia Roli Madubuko
MNMaureen Ntaji
Maureen Ntaji
JOJohn Oghenevwirhe Ohaju-Obodo
John Oghenevwirhe Ohaju-Obodo

31 May 2018 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
AOAbimbola O. Opadeyi
Abimbola O. Opadeyi
AFAnnie Fourrier-Réglat
Annie Fourrier-Réglat
AIAmbrose O. Isah
Ambrose O. Isah
WHO pharmacovigilance indicators have been recommended as a useful tool towards improving pharmacovigilance activities. Nigeria with a myriad of medicines related issues is encouraging the growth of pharmacovigilance at peripheral centres. This study evaluated the status of pharmacovigilance in tertiary hospitals in the South-South zone of Nigeria with a view towards improving the pharmacovigilance system in the zone. A cross-sectional descriptive survey was conducted in six randomly selected tertiary hospitals in the South-South zone of the country. The data was collected using the WHO core pharmacovigilance indicators. The language of assessment was phrased and adapted in this study for use in a tertiary hospital setting. Data is presented quantitatively and qualitatively. A total of six hospitals were visited and all institutions had a pharmacovigilance centre, only three could however be described as functional or partially functional. Only one centre had a financial provision for pharmacovigilance activities. Of note was the absence of the national adverse drug reaction reporting form in one of the hospitals. The number of adverse drug reaction reports found in the databases of the centres ranged from none to 26 for the previous year and only one centre had fully committed their reports to the National Pharmacovigilance Centre. There were few documented medicines related admissions ranging from 0.0985/1000 to 1.67/1000 and poor documentation of pharmacovigilance activities characterised all centres. This study has shown an urgent need to strengthen the pharmacovigilance systems in the South-South zone of Nigeria. Improvement in medical record documentation as well as increased institutionalization of pharmacovigilance may be the first steps to improve pharmacovigilance activities in the tertiary hospitals.

25 January 2019 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
PDF file
AOAbimbola O. Opadeyi
Abimbola O. Opadeyi
AFAnnie Fourrier-Réglat
Annie Fourrier-Réglat
AIAmbrose O. Isah
Ambrose O. Isah
Our aim in this study was to evaluate the effect of a combined educational intervention and year-long monthly text message reinforcements via the Short Messaging System (SMS) on the knowledge, attitude and practice (KAP) of healthcare professionals (HCPs) towards pharmacovigilance. Six randomly selected teaching hospitals in the South-South zone of Nigeria were randomized in 1:1 ratio into intervention and control groups. The educational intervention consisted of delivering a seminar followed by sending monthly texts message reinforcements via SMS over 12 months. Then a semi-structured questionnaire regarding the KAP of pharmacovigilance was completed by HCPs working in the hospitals after the intervention. Data was analysed descriptively and inferentially. A total of 931 HCPs participated in the post intervention study (596 in the intervention and 335 in the control). The M:F ratio was 1:1.5. According to the KAP questionnaire, a significant difference was observed between the intervention and control groups, regarding knowledge of the types of adverse drug reactions (ADRs). ADR resulting from pharmacological action of the drug (85.6% versus 77%, p = 0.001), the fact that ADRs can persist for a long time; (60.1% versus 53.4%, p = 0.024) and a higher awareness of the ADR reporting form (48.7% versus 18.8%, p < 0.001). Most respondents in the intervention group (68.5% versus 60.6%, p = 0.001) believed they should report ADRs even if they were unsure an ADR has occurred, a greater proportion of HCPs from the intervention group had significantly observed an ADR (82% versus 73.4%, p = 0.001). Furthermore, of the 188 who had ever reported an ADR, 41% from the intervention group used the national ADR reporting form compared with 19.8% from the controls (p < 0.001). This educational intervention and the use of SMS as a reinforcement tool appeared to have positively impacted on the knowledge and practice of pharmacovigilance in South-South Nigeria with a less-than-impressive change in attitude. Continuous medical education may be required to effect long-lasting changes.

19 January 2016 in Pharmaceutical Medicine
Verified
Journal Article
Closed access
PDF file
AOAbimbola Olowofela
Abimbola Olowofela
AFAnnie Fourrier-Réglat
Annie Fourrier-Réglat
AIAmbrose O. Isah
Ambrose O. Isah

1 January 2023 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
AIAmbrose O. Isah
Ambrose O. Isah
AOAbimbola O. Opadeyi
Abimbola O. Opadeyi
HTHenry Tumwijukye
Henry Tumwijukye
FCFrank Cobelens
Frank Cobelens
DSDiede Smith
Diede Smith
JPJayesh M. Pandit
Jayesh M. Pandit
Background: An important factor hindering the growth of pharmacovigilance (PV) in resource-limited settings is the lack of adequate funds to establish a functional National Pharmacovigilance System. Consequently, the crucial function of monitoring and ensuring the availability of safe medicines in these settings cannot be guaranteed considering the peculiarities of diseases and medicines used. Objectives: The objective of this paper is to provide an overview as to the availability of potential sources of funds, which could be explored to ensure Medicine Safety and to proffer a potential framework likely to ensure sustainable funding of PV in Africa. Methods/processes: The process of developing this framework entailed a review of PV financing in some developed economies, a landscape study of funding of PV in some African countries, an in-depth understanding of the PV system and the organisational structure and nexus between the regulatory agencies and National Pharmacovigilance Centre. Critical points for consideration included the sources of funds, revenue pool, the disbursement of funds, budgeting and expenditure profile and the legal framework. Consultative meetings, webinars and interviews with experts were carried out. Results: The findings showed that most of the PV systems were mainly integrated into the regulatory agencies regarding operational and fiscal governance with few facilities being independent of the regulatory agencies. The main source of funding was from the government with significant donor funding which is ad hoc and non-sustainable. Several potential sources were identified but yet to be exploited. There were no legal provisions for PV financing. A framework likely to ensure sustainable PV financing is suggested to capture all available sources of funding, mine the potential sources providing a sizeable pool of revenue to address its activities and enabling legal framework which will engender autonomy. Furthermore, it will address the nexus between the regulatory agencies and the PV outfits, thus enabling appropriate share of resources and blockage of diversions. Conclusion: In all, addressing the various elements identified in this study and providing the legal provisions which guarantees some degree of autonomy will provide a sustainable mechanism for PV funding in the resource-limited setting of Africa.